Medical News |
- Extreme psoriasis increases mortality risk, not through CVD
- UK acute upper GI bleed rates declining
- UK acute upper GI bleed rates declining
- Longer INR follow-up interval linked to worse anticoagulation control
- Third ventricle involvement predicts ICH outcomes
- Tamoxifen compliance low in younger breast cancer survivors
- Combination therapy reduces sPLA2 activity
- Dietary advice can reduce saturated fat intake in children
- Angiography patients often have undetected diabetes and IGT
- Microvascular risk differs with gender and age at onset of Type 1 diabetes
- Use of evidence-based STEMI treatments cuts mortality risk
- Morning MIs linked to larger infarct size
- Tamoxifen compliance low in younger breast cancer survivors
| Extreme psoriasis increases mortality risk, not through CVD Posted: 28 Apr 2011 05:00 PM PDT Patients with "exceptionally severe" psoriasis have an increased mortality risk compared with those with less extreme forms of the condition, but as a result of diseases other than cardiovascular disease, report researchers. |
| UK acute upper GI bleed rates declining Posted: 28 Apr 2011 05:00 PM PDT Findings from a 2007 UK audit show that rates of acute upper gastrointestinal bleeding have fallen by 4% since 1993. |
| UK acute upper GI bleed rates declining Posted: 28 Apr 2011 05:00 PM PDT Findings from a 2007 UK audit show that rates of acute upper gastrointestinal bleeding have fallen by 4% since 1993. |
| Longer INR follow-up interval linked to worse anticoagulation control Posted: 27 Apr 2011 05:00 PM PDT The interval between an initial out-of-range international normalized ratio value and a repeat test varies widely from clinic to clinic, even though long follow-up intervals are associated with worse anticoagulation control, US researchers report. |
| Third ventricle involvement predicts ICH outcomes Posted: 27 Apr 2011 05:00 PM PDT The volume of blood in the third ventricle is strong predictor of outcome in patients with intracerebral hemorrhage with severe ventricular involvement, research shows. |
| Tamoxifen compliance low in younger breast cancer survivors Posted: 27 Apr 2011 05:00 PM PDT Approximately half of women under 40 years of age with breast cancer discontinue tamoxifen therapy within 5 years of treatment initiation, study findings indicate. |
| Combination therapy reduces sPLA2 activity Posted: 27 Apr 2011 05:00 PM PDT Treatment with atorvastatin plus ezetimibe can significantly reduce the activity of secretory phospholipase A2 in patients with coronary artery disease, study results show. |
| Dietary advice can reduce saturated fat intake in children Posted: 27 Apr 2011 05:00 PM PDT Australian researchers say that promoting the consumption of reduced-fat dairy foods can significantly reduce saturated fat, but not energy, intake in children. |
| Angiography patients often have undetected diabetes and IGT Posted: 27 Apr 2011 05:00 PM PDT Previously undetected impaired glucose tolerance and Type 2 diabetes are common in patients undergoing angiography for suspected angina, suggest study results. |
| Microvascular risk differs with gender and age at onset of Type 1 diabetes Posted: 27 Apr 2011 05:00 PM PDT The risk for developing microvascular complications in adulthood among people with Type 1 diabetes is highly dependent on gender and age-at-onset of diabetes, say researchers. |
| Use of evidence-based STEMI treatments cuts mortality risk Posted: 27 Apr 2011 05:00 PM PDT The increasing use of evidence-based, guideline-recommended treatments for ST-elevation myocardial infarction has been accompanied by "large and sustained" reductions in mortality, an analysis of Swedish registry data reveals. |
| Morning MIs linked to larger infarct size Posted: 27 Apr 2011 05:00 PM PDT Infarct size varies according to the time of day that an ST-segment elevation myocardial infarction occurs, research from Spain suggests. |
| Tamoxifen compliance low in younger breast cancer survivors Posted: 27 Apr 2011 05:00 PM PDT Approximately half of women under 40 years of age with breast cancer discontinue tamoxifen therapy within 5 years of treatment initiation, study findings indicate. |
| You are subscribed to email updates from MedWire Medical News Combined Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |